Bradycardia Treatment Devices Market Report 2026

Bradycardia Treatment Devices Market Overview

• Bradycardia Treatment Devices market size has reached to $8.97 billion in 2025 • Expected to grow to $11.51 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Impact Of Cardiovascular Disease Prevalence On The Bradycardia Treatment Devices Market • Market Trend: Advancements In Bradycardia Treatment With Leadless Pacemaker Systems • North America was the largest region in 2025.

What Is Covered Under Bradycardia Treatment Devices Market?

Bradycardia treatment devices are specialized tools used in medical settings to address slow heart rates, ensuring the heart maintains a healthy rhythm and adequate blood flow throughout the body. These devices are crucial for managing cardiac conditions and supporting cardiovascular health. The main devices of bradycardia treatment devices are pacemakers and defibrillators. Pacemakers are medical devices that regulate the heartbeat by delivering electrical impulses to the heart. They are used in the treatment of conditions such as sinus bradycardia, sinus pause, sick sinus syndrome, tachy-brady syndrome, and heart block. These devices are utilized by end users such as hospitals, specialty clinics, and other healthcare facilities.

What Is The Bradycardia Treatment Devices Market Growth Forecast?

The bradycardia treatment devices market size is expected to see steady growth in the next few years. It will grow to $11.51 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to growing demand for mri-conditional and biventricular pacemakers, rising uptake of external and wearable defibrillators, increasing treatment rates for sick sinus syndrome and heart block, higher adoption of device-based rhythm stabilization in aging patients, expanding use of cardiac rhythm therapy in specialty clinics. Major trends in the forecast period include increasing development of advanced implantable pacemaker technologies, growing use of bradycardia devices in cardiac rhythm management therapies, rising preference for minimally invasive cardiac device implantation procedures, expansion of device usage across multiple bradycardia-related cardiac conditions, focus on enhancing device safety, longevity, and treatment reliability.

Global Bradycardia Treatment Devices Market Segmentation

1) By Devices: Pacemakers, Defibrillator 2) By Treatment Type: Sinus Bradycardia, Sinus Pause, Sick Sinus Syndrome, Tachy-Brady Syndrome, Heart Block 3) By End User: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Pacemakers: Single Chamber Pacemakers, Dual Chamber Pacemakers, Biventricular Pacemakers, MRI-Conditional Pacemakers, External Pacemakers 2) By Defibrillator: Implantable Cardioverter Defibrillators (ICDS), External Defibrillators, Automated External Defibrillators (AEDS), Manual External Defibrillators, Wearable Defibrillators

What Is The Driver Of The Bradycardia Treatment Devices Market?

The rising prevalence of cardiovascular disease is expected to propel the growth of the bradycardia treatment devices market going forward. Cardiovascular disease refers to conditions affecting the heart and blood vessels, including coronary artery disease, stroke, and heart failure. The increasing prevalence of cardiovascular disease can be attributed to factors such as sedentary lifestyles, poor diets, smoking, and aging populations. Bradycardia treatment devices, such as pacemakers, are used to regulate heart rhythm and maintain an adequate heart rate in patients with cardiac disorders. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular disease will drive the growth of the bradycardia treatment devices industry.

Key Players In The Global Bradycardia Treatment Devices Market

Major companies operating in the bradycardia treatment devices market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, MicroPort Scientific Corporation, LivaNova PLC, Osypka Medical GmbH, Lepu Medical Technology Co Ltd, Pacetronix Ltd, Shree Pacetronix Ltd, Medico SpA, Zoll Medical Corporation, EBR Systems Inc, Impulse Dynamics NV, Cardioelectronica Company, IMZ Medical Devices, Oscor Inc, CCC Medical Devices, Atacor Medical, Koninklijke Philips NV

Global Bradycardia Treatment Devices Market Trends and Insights

Major companies operating in bradycardia treatment devices are focused on developing advanced solutions, such as leadless pacemakers, to improve patient outcomes and reduce procedural complications. Leadless pacemakers refer to the small, self-contained devices implanted directly into the heart without the use of leads, offering a minimally invasive option for controlling heart rhythm. For instance, in July 2023, Abbott Laboratories, a US-based medical device manufacturing company, received US Food and Drug Administration (FDA) approval for the AVEIR dual chamber (DR) leadless pacemaker system. It is a dual-chamber leadless pacing system that treats people with abnormal or slow heart rhythms. It offers synchronized or coordinated cardiac pacing between two leadless pacemakers, tailored to meet the individual's clinical requirements.

What Are Latest Mergers And Acquisitions In The Bradycardia Treatment Devices Market?

In January 2024, Integer Holdings Corporation, a US‑based provider of contract manufacturing services for medical devices (including electrophysiology and leadless pacing), acquired Pulse Technologies, Inc. for US$ 140 million. With this acquisition, Integer expanded its end‑to‑end manufacturing footprint in growth areas like leadless pacemakers, thereby enhancing its capacity to serve bradycardia or CRM device makers. Pulse Technologies is a US-based engineering and manufacturing company providing micro‑machined components for medical device companies in structural heart, electrophysiology, and leadless pacing.

Regional Outlook

North America was the largest region in the bradycardia treatment devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Bradycardia Treatment Devices Market?

The bradycardia treatment devices market consists of sales of implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and leadless pacemakers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.